CA2467973C - Pyridine derivatives as nmda receptor ligands - Google Patents

Pyridine derivatives as nmda receptor ligands Download PDF

Info

Publication number
CA2467973C
CA2467973C CA002467973A CA2467973A CA2467973C CA 2467973 C CA2467973 C CA 2467973C CA 002467973 A CA002467973 A CA 002467973A CA 2467973 A CA2467973 A CA 2467973A CA 2467973 C CA2467973 C CA 2467973C
Authority
CA
Canada
Prior art keywords
compound
pyridin
dihydro
addition salt
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002467973A
Other languages
English (en)
French (fr)
Other versions
CA2467973A1 (en
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2467973A1 publication Critical patent/CA2467973A1/en
Application granted granted Critical
Publication of CA2467973C publication Critical patent/CA2467973C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002467973A 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands Expired - Fee Related CA2467973C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
EP01126467.8 2001-11-09
PCT/EP2002/012240 WO2003040128A1 (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Publications (2)

Publication Number Publication Date
CA2467973A1 CA2467973A1 (en) 2003-05-15
CA2467973C true CA2467973C (en) 2009-09-01

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467973A Expired - Fee Related CA2467973C (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Country Status (16)

Country Link
US (1) US6831087B2 (https=)
EP (1) EP1448547B1 (https=)
JP (1) JP4188837B2 (https=)
KR (1) KR100589995B1 (https=)
CN (1) CN100516061C (https=)
AR (1) AR037221A1 (https=)
AT (1) ATE293619T1 (https=)
AU (1) AU2002351816B8 (https=)
BR (1) BR0213977A (https=)
CA (1) CA2467973C (https=)
DE (1) DE60203820T2 (https=)
ES (1) ES2240829T3 (https=)
MX (1) MXPA04004308A (https=)
PL (1) PL369544A1 (https=)
RU (1) RU2303037C2 (https=)
WO (1) WO2003040128A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
WO2009065922A2 (de) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
RU2303037C2 (ru) 2007-07-20
US6831087B2 (en) 2004-12-14
DE60203820T2 (de) 2006-02-23
RU2004117595A (ru) 2006-01-10
CN100516061C (zh) 2009-07-22
MXPA04004308A (es) 2004-08-11
EP1448547A1 (en) 2004-08-25
AU2002351816B2 (en) 2008-03-06
JP4188837B2 (ja) 2008-12-03
ATE293619T1 (de) 2005-05-15
US20030119870A1 (en) 2003-06-26
CN1585762A (zh) 2005-02-23
PL369544A1 (en) 2005-05-02
CA2467973A1 (en) 2003-05-15
EP1448547B1 (en) 2005-04-20
BR0213977A (pt) 2004-08-31
ES2240829T3 (es) 2005-10-16
AU2002351816B8 (en) 2008-04-03
JP2005513004A (ja) 2005-05-12
AR037221A1 (es) 2004-10-27
WO2003040128A1 (en) 2003-05-15
KR20050042252A (ko) 2005-05-06
KR100589995B1 (ko) 2006-06-19
DE60203820D1 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
CA2467973C (en) Pyridine derivatives as nmda receptor ligands
AU2019206032B2 (en) Radiolabelled derivatives of a 2-amino-6-fluoro-N-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
AU2002304800B2 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
CA2306093C (en) Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
FI96768B (fi) Menetelmä valmistaa farmakologisesti arvokasta bentso/5,6/sykloheptapyridiiniä
AU2002351816A1 (en) Pyridine Substituted Isoquinoline Derivatives
TW200306180A (en) New compounds
CN1980923A (zh) 多环吡啶作为钾离子通道调节剂
SK70899A3 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
CA2393672A1 (en) Selective neurokinin antagonists
CN108017641A (zh) 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR100591935B1 (ko) Ｎｍｄａ-수용체 아형 차단제로서의 피리딘 유도체
KR20220052333A (ko) 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
WO1993019062A1 (en) Tetrahydropyridine isoxazoline derivatives
EP2496579B1 (en) 1-substituted 2-azabicyclo[3.1.1]heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders
KR20100119789A (ko) 2-아미노퀴놀린
AU2016378154B2 (en) Phenylimidazole compound
AU2002349396A1 (en) Pyridine derivatives as NMDA-receptor subtype blockers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed